

# Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor- $\alpha$ inhibitors

Piera Altieri, Francesco Maria Mariani, Evy Di Ruscio, Francesco Carubbi, Claudio Ferri, Alessia Alunno

Department of Life, Health and Environmental Sciences, University of L'Aquila; Internal Medicine and Nephrology Division, ASL1 Avezano-Sulmona-L'Aquila, San Salvatore Hospital, L'Aquila, Italy

**Correspondence:** Francesco Carubbi, Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy.  
E-mail: francescocarubbi@libero.it

**Key words:** case report, ankylosing spondylitis, thymoma.

## Summary

Thymic tumors are rare in the general population, and to the best of our knowledge, no cases of thymoma have been described in patients with rheumatic diseases treated with tumor necrosis factor (TNF)- $\alpha$  inhibitors, except for the case of a patient receiving infliximab for Crohn's disease (CD) who developed a B2 thymoma. We describe a 60-year-old Caucasian male with radiographic axial spondyloarthritis (r-axSpA) and CD who developed an AB-type thymoma without myasthenia gravis after 18 years of treatment with TNF- $\alpha$  inhibitors. The patient had received the same molecule since the r-axSpA/CD diagnosis and changed it 6 months before the diagnosis of thymoma due to a disease flare. At the time of the drug switch, no mediastinal mass was present on the chest X-ray. The thymoma was surgically removed, and no additional therapy was needed. Treatment with TNF- $\alpha$  inhibitors was reintroduced after surgery. This case raises some important questions that remain open and deserve to be addressed in the future, such as the association between immunosuppressive therapy and thymoma and the controversial relationship between TNF- $\alpha$  inhibitors and myasthenia gravis.

## Introduction

Thymic tumors are a rare, albeit heterogeneous, group of malignancies with a broad range of clinical presentations. Thymoma is the most frequent subtype, with an estimated incidence of 0.13-0.32/100,000/year and accounting for 0.2-1.5% of all malignancies (1). Thymomas are associated with autoimmune diseases more often than other malignancies. Herein, we report the case of a patient with radiographic axial spondyloarthritis (r-axSpA) and Crohn's disease (CD) developing thymoma without myasthenia gravis (MG) following treatment with biologic disease-modifying anti-rheumatic drugs.

## Case Report

We describe the case of a 60-year-old Caucasian man with r-

axSpA and CD, both diagnosed in 2004, arterial hypertension, dyslipidemia, and cluster headache. He had been successfully treated with adalimumab since r-axSpA/CD diagnosis, but in April 2022, a peripheral disease flare occurred and adalimumab was withdrawn [Disease Activity Score (DAS) 44 = 3.22; Ankylosing Spondylitis DAS (ASDAS) = 2.7]. Screening exams for hepatitis B and C viruses, and tuberculosis (also including a chest X-ray) were performed, and all results were normal; therefore, golimumab 50 mg monthly was started. Within 3 months, remission was achieved (DAS44=1.6, ASDAS=1.3). In December 2022, an episode of dyspnea and chest pain occurred, and the patient performed another chest X-ray, which showed the presence of a mediastinal mass, confirmed by chest computed tomography scan (Figure 1). The radiologist reported the mass being in close continuity with the anterolateral profile of the ascending aorta, as well as with the right atrium and superior vena cava. The patient had neither symptoms nor clinical/serological abnormalities, suggesting a concomitant autoimmune disease. Good's syndrome was also ruled out since circulating gamma globulins were normal. The mass was surgically removed, and its histological assessment was consistent with a type AB thymoma (1). Post-surgical oncology consultation did not deem appropriate further treatments, such as chemotherapy or radiotherapy, and recommended restarting golimumab to prevent AS/CD flares.

## Discussion

Long-term safety data on biologic disease-modifying anti-rheumatic drugs and cancer have accrued, showing a comparable or minimally increased risk in patients with rheumatic diseases receiving these drugs (2, 3). To the best of our knowledge, no cases of thymoma have been described in patients with rheumatic diseases treated with tumor necrosis factor (TNF)- $\alpha$  inhibitors. Only another case of a patient receiving infliximab for CD who developed a B2 thymoma has been previously published (4).

Thymic tumors are a rare, albeit heterogeneous, group of malignancies with a broad range of clinical presentations. Thymoma is the most frequent subtype with an estimated incidence of 0.13-0.32/100,000/year and accounts for 0.2-1.5% of all malignancies (1, 5). Thymomas are associated with autoimmune

diseases far more often than other malignancies, which is not surprising due to the pivotal role of the thymus in shaping the immune system and fine-tuning the immune responses during early stages of life. Although the exact mechanisms underlying the development of autoimmune diseases in patients with thymoma are not yet fully elucidated, it is well established that perturbances of the thymic microenvironment alongside reduced expression of the autoimmune regulator gene and major histocompatibility class II lead to a reduction of regulatory T-cells and, as a consequence, to an impaired immune tolerance (6). Regarding inflammatory bowel diseases, thymoma rarely occurs in patients with these conditions. Available studies have reported that ulcerative colitis was combined with thymoma in 0.3% of patients, whereas the burden of thymoma in CD is unknown (7-9).

MG may occur in up to 40% of patients with thymoma and, therefore, is the most frequently observed autoimmune disease (6). B1 and B2 thymomas are the histological subtypes most frequently associated with MG, but MG was also described in patients with AB thymoma and patients with thymic conditions other than thymoma, such as thymic follicular hyperplasia or thymic atrophy (6, 10). MG results from autoantibody-mediated damage at the neuromuscular junctions, selectively targeting acetylcholine receptors, and is characterized by clinical features including weakness and fatigability in skeletal muscles (11). The role of TNF- $\alpha$  in the pathogenesis of MG has been extensively investigated, and in the past, the possible application of TNF- $\alpha$  blockers for MG treatment was also put forward (12, 13). However, the evidence that TNF- $\alpha$  serum levels broadly vary in patients with MG and are not correlated with the clinical picture, as well as the demonstration that MG may be induced by TNF- $\alpha$  blockers used for other indications, dampened the enthusiasm towards this putative new treatment for MG (14-17).



**Figure 1.** Computed tomography scan showing the mediastinal mass.

## Conclusions

In conclusion, the case that we presented raises some important questions that remain open and deserve to be addressed in the future. First, whether the patient developed the thymoma due to long-term immunosuppression with TNF- $\alpha$  inhibitors or whether he would have developed this neoplasm regardless of the therapy. Second, whether the type of TNF- $\alpha$  inhibitor may have played a role in the development of thymoma since it occurred 8 months after starting golimumab (no evidence of the lesion on the chest X-ray performed at adalimumab withdrawal). Third, whether the thymoma developed due to the concomitant presence of r-axSpA/CD, and finally, whether the patient did not develop MG because he was within the 60% of patients with thymoma that do not develop MG, or because the long-term treatment with TNF- $\alpha$  inhibitors may have exerted some sort of protection towards autoimmunity.

## References

1. Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? *J Thorac Oncol* 2022; 17: 200-13.
2. Huss V, Bower H, Hellgren K, Frisell T, Askling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. *Ann Rheum Dis* 2023; 82: 911-9.
3. Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B, et al. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. *RMD Open* 2022; 8: e002139.
4. Konso M, El Bacha H, Dilal S, Mendes P, Znati K, Benzoubeir N, et al. Development of thymoma during anti-TNF alpha therapy: coincidence or consequence. *IAR J Med Cse Rep* 2023; 4: 19-21.
5. Rich AL. Epidemiology of thymoma. *J Thorac Dis* 2020; 12: 7531-5.
6. Blum TG, Misch D, Kollmeier J, Thiel S, Bauer TT. Autoimmune disorders and paraneoplastic syndromes in thymoma. *J Thorac Dis* 2020; 12: 7571-90.
7. Souadjian JV, Enriquez P, Silverstein MN, Pepin JM. The spectrum of diseases associated with thymoma. *Arch Intern Med* 1974; 134: 374-9.
8. Teramatsu T, Yamamoto H, Matsutani Y. Mediastinal tumors in Japan survey. *Jpn J Thorac Surg* 1976; 24: 270-3.
9. Okubo K, Kondo N, Okamoto T, Isobe J, Ueno Y. Excision of an invasive thymoma: a cure for ulcerative colitis? *Case Reports Ann Thorac Surg* 2001; 71: 2013-5.
10. De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L, et al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. *Thorac Cancer* 2021; 12: 106-13.
11. Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. *J Autoimmun* 2014; 52: 90-100.
12. Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R. Therapeutic options in autoimmune

- myasthenia gravis. *Autoimmun Rev* 2007; 6: 373-8.
13. Rodolico C, Nicocia G, Damato V, Antonini G, Liguori R, Evoli A. Benefit and danger from immunotherapy in myasthenia gravis. *Neurol Sci* 2021; 42: 1367-75.
  14. Lee JS, Joo IS, Seok JI. Widely varying TNF-alpha levels in patients with myasthenia gravis. *Neurol Sci* 2009; 30: 259-62.
  15. Bruzzese V, Marrese C, Scolieri P, Hassan C, Lorenzetti R, Zullo A. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy? *Int J Rheum Dis* 2015; 18: 375-6.
  16. Nicocia G, Bonanno C, Lupica A, Toscano A, Rodolico C. Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: a case report. *Neuromuscul Disord* 2020; 30: 246-9.
  17. Pelechas E, Memi T, Markatseli TE, Voulgari PV, Drosos AA. Adalimumab-induced myasthenia gravis: case-based review. *Rheumatol Int* 2020; 40: 1891-4.

Contributions: all the authors made a substantial intellectual contribution, read and approved the final version of the manuscript, and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: not applicable.

Patient consent for publication: the patient provided consent to use their anonymised medical information in this case report.

Availability of data and materials: all data underlying the findings are fully available.

Funding: none.

Received: 12 December 2023.

Accepted: 18 September 2024.

Early access: 5 June 2025.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

*Reumatismo* 2025; 77:1693

doi:10.4081/reumatismo.2025.1693

*Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*